Selected research
Industry Research
Tumor Fluid Biopsy Industry Research Report 2026
Market perspective
The global Tumor Fluid Biopsy market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Tumor Fluid Biopsy market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Tumor Fluid Biopsy market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Tumor Fluid Biopsy market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Tumor Fluid Biopsy include Cellmax Life, Exact Science, Amoy Diagnostics Co, Berry Genomics Co, Genetronhealth, GenoploRare, HaploX Biotechnology Co, New Horizon Health Limited and Burning Rock Biotech, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Tumor Fluid Biopsy market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Tumor Fluid Biopsy.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Tumor Fluid Biopsy Market by Company
Cellmax Life
Exact Science
Amoy Diagnostics Co
Berry Genomics Co
Genetronhealth
GenoploRare
HaploX Biotechnology Co
New Horizon Health Limited
Burning Rock Biotech
Guangzhou Wondfo Biotech
YZY Biopharma
Tumor Fluid Biopsy Segment by Type
CTDNA Detection
CTC Detection
Other
Tumor Fluid Biopsy Segment by Application
Hospital
Third Party Organization
Other
Tumor Fluid Biopsy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Fluid Biopsy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tumor Fluid Biopsy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Fluid Biopsy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Tumor Fluid Biopsy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CTDNA Detection
- CTC Detection
- Other
Applications
- Hospital
- Third Party Organization
- Other
Companies covered
- Cellmax Life
- Exact Science
- Amoy Diagnostics Co
- Berry Genomics Co
- Genetronhealth
- GenoploRare
- HaploX Biotechnology Co
- New Horizon Health Limited
- Burning Rock Biotech
- Guangzhou Wondfo Biotech
- YZY Biopharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Tumor Fluid Biopsy by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 CTDNA Detection
- 2.2.3 CTC Detection
- 2.2.4 Other
- 2.3 Tumor Fluid Biopsy by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Third Party Organization
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Tumor Fluid Biopsy Breakdown Data by Type
- 3.1 Global Tumor Fluid Biopsy Historic Market Size by Type (2021-2026)
- 3.2 Global Tumor Fluid Biopsy Forecasted Market Size by Type (2027-2032)
4 Tumor Fluid Biopsy Breakdown Data by Application
- 4.1 Global Tumor Fluid Biopsy Historic Market Size by Application (2021-2026)
- 4.2 Global Tumor Fluid Biopsy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Tumor Fluid Biopsy Market Perspective (2021-2032)
- 5.2 Global Tumor Fluid Biopsy Growth Trends by Region
- 5.2.1 Global Tumor Fluid Biopsy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Tumor Fluid Biopsy Historic Market Size by Region (2021-2026)
- 5.2.3 Tumor Fluid Biopsy Forecasted Market Size by Region (2027-2032)
- 5.3 Tumor Fluid Biopsy Market Dynamics
- 5.3.1 Tumor Fluid Biopsy Industry Trends
- 5.3.2 Tumor Fluid Biopsy Market Drivers
- 5.3.3 Tumor Fluid Biopsy Market Challenges
- 5.3.4 Tumor Fluid Biopsy Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Tumor Fluid Biopsy Players by Revenue
- 6.1.1 Global Top Tumor Fluid Biopsy Players by Revenue (2021-2026)
- 6.1.2 Global Tumor Fluid Biopsy Revenue Market Share by Players (2021-2026)
- 6.2 Global Tumor Fluid Biopsy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Tumor Fluid Biopsy Head Office and Area Served
- 6.4 Global Tumor Fluid Biopsy Players, Product Type & Application
- 6.5 Global Tumor Fluid Biopsy Manufacturers Established Date
- 6.6 Global Tumor Fluid Biopsy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Tumor Fluid Biopsy Market Size (2021-2032)
- 7.2 North America Tumor Fluid Biopsy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Tumor Fluid Biopsy Market Size by Country (2021-2026)
- 7.4 North America Tumor Fluid Biopsy Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Tumor Fluid Biopsy Market Size (2021-2032)
- 8.2 Europe Tumor Fluid Biopsy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Tumor Fluid Biopsy Market Size by Country (2021-2026)
- 8.4 Europe Tumor Fluid Biopsy Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Tumor Fluid Biopsy Market Size (2021-2032)
- 9.2 Asia-Pacific Tumor Fluid Biopsy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Tumor Fluid Biopsy Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Tumor Fluid Biopsy Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Tumor Fluid Biopsy Market Size (2021-2032)
- 10.2 South America Tumor Fluid Biopsy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Tumor Fluid Biopsy Market Size by Country (2021-2026)
- 10.4 South America Tumor Fluid Biopsy Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Tumor Fluid Biopsy Market Size (2021-2032)
- 11.2 Middle East & Africa Tumor Fluid Biopsy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Tumor Fluid Biopsy Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Tumor Fluid Biopsy Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Cellmax Life
- 12.1.1 Cellmax Life Company Information
- 12.1.2 Cellmax Life Business Overview
- 12.1.3 Cellmax Life Revenue in Tumor Fluid Biopsy Business (2021-2026)
- 12.1.4 Cellmax Life Tumor Fluid Biopsy Product Portfolio
- 12.1.5 Cellmax Life Recent Developments
- 12.2 Exact Science
- 12.2.1 Exact Science Company Information
- 12.2.2 Exact Science Business Overview
- 12.2.3 Exact Science Revenue in Tumor Fluid Biopsy Business (2021-2026)
- 12.2.4 Exact Science Tumor Fluid Biopsy Product Portfolio
- 12.2.5 Exact Science Recent Developments
- 12.3 Amoy Diagnostics Co
- 12.3.1 Amoy Diagnostics Co Company Information
- 12.3.2 Amoy Diagnostics Co Business Overview
- 12.3.3 Amoy Diagnostics Co Revenue in Tumor Fluid Biopsy Business (2021-2026)
- 12.3.4 Amoy Diagnostics Co Tumor Fluid Biopsy Product Portfolio
- 12.3.5 Amoy Diagnostics Co Recent Developments
- 12.4 Berry Genomics Co
- 12.4.1 Berry Genomics Co Company Information
- 12.4.2 Berry Genomics Co Business Overview
- 12.4.3 Berry Genomics Co Revenue in Tumor Fluid Biopsy Business (2021-2026)
- 12.4.4 Berry Genomics Co Tumor Fluid Biopsy Product Portfolio
- 12.4.5 Berry Genomics Co Recent Developments
- 12.5 Genetronhealth
- 12.5.1 Genetronhealth Company Information
- 12.5.2 Genetronhealth Business Overview
- 12.5.3 Genetronhealth Revenue in Tumor Fluid Biopsy Business (2021-2026)
- 12.5.4 Genetronhealth Tumor Fluid Biopsy Product Portfolio
- 12.5.5 Genetronhealth Recent Developments
- 12.6 GenoploRare
- 12.6.1 GenoploRare Company Information
- 12.6.2 GenoploRare Business Overview
- 12.6.3 GenoploRare Revenue in Tumor Fluid Biopsy Business (2021-2026)
- 12.6.4 GenoploRare Tumor Fluid Biopsy Product Portfolio
- 12.6.5 GenoploRare Recent Developments
- 12.7 HaploX Biotechnology Co
- 12.7.1 HaploX Biotechnology Co Company Information
- 12.7.2 HaploX Biotechnology Co Business Overview
- 12.7.3 HaploX Biotechnology Co Revenue in Tumor Fluid Biopsy Business (2021-2026)
- 12.7.4 HaploX Biotechnology Co Tumor Fluid Biopsy Product Portfolio
- 12.7.5 HaploX Biotechnology Co Recent Developments
- 12.8 New Horizon Health Limited
- 12.8.1 New Horizon Health Limited Company Information
- 12.8.2 New Horizon Health Limited Business Overview
- 12.8.3 New Horizon Health Limited Revenue in Tumor Fluid Biopsy Business (2021-2026)
- 12.8.4 New Horizon Health Limited Tumor Fluid Biopsy Product Portfolio
- 12.8.5 New Horizon Health Limited Recent Developments
- 12.9 Burning Rock Biotech
- 12.9.1 Burning Rock Biotech Company Information
- 12.9.2 Burning Rock Biotech Business Overview
- 12.9.3 Burning Rock Biotech Revenue in Tumor Fluid Biopsy Business (2021-2026)
- 12.9.4 Burning Rock Biotech Tumor Fluid Biopsy Product Portfolio
- 12.9.5 Burning Rock Biotech Recent Developments
- 12.10 Guangzhou Wondfo Biotech
- 12.10.1 Guangzhou Wondfo Biotech Company Information
- 12.10.2 Guangzhou Wondfo Biotech Business Overview
- 12.10.3 Guangzhou Wondfo Biotech Revenue in Tumor Fluid Biopsy Business (2021-2026)
- 12.10.4 Guangzhou Wondfo Biotech Tumor Fluid Biopsy Product Portfolio
- 12.10.5 Guangzhou Wondfo Biotech Recent Developments
- 12.11 YZY Biopharma
- 12.11.1 YZY Biopharma Company Information
- 12.11.2 YZY Biopharma Business Overview
- 12.11.3 YZY Biopharma Revenue in Tumor Fluid Biopsy Business (2021-2026)
- 12.11.4 YZY Biopharma Tumor Fluid Biopsy Product Portfolio
- 12.11.5 YZY Biopharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst